BETA 2 GLYCOPROTEIN 1 IGA

The Beta 2 Glycoprotein 1 (β2GP1) IgA Antibody Test is a specialized blood test that detects Immunoglobulin A (IgA) autoantibodies against Beta 2 Glycoprotein 1 (β2GP1), a plasma protein involved in regulating blood clotting and maintaining normal vascular function. This test is primarily used in the evaluation of Antiphospholipid Syndrome (APS), an autoimmune disorder that increases the risk of abnormal blood clot formation and pregnancy-related complications.

In Antiphospholipid Syndrome, the immune system mistakenly produces antibodies against phospholipid-binding proteins such as Beta 2 Glycoprotein 1. These antibodies may interfere with the body's normal clotting mechanisms, increasing the risk of deep vein thrombosis (DVT), pulmonary embolism, stroke, and recurrent pregnancy loss.

Although IgG and IgM Beta 2 Glycoprotein 1 antibodies are included in the laboratory classification criteria for APS, IgA antibodies may provide additional diagnostic value in selected patients, particularly when clinical suspicion remains high despite negative IgG and IgM results.

The Beta 2 Glycoprotein 1 IgA Antibody Test is commonly performed together with Beta 2 Glycoprotein 1 IgG and IgM, Anticardiolipin antibodies (IgG, IgM, IgA), and Lupus Anticoagulant testing to provide a comprehensive evaluation for antiphospholipid syndrome.

Benefits of the Test

• Detects Beta 2 Glycoprotein 1 IgA autoantibodies
• Supports evaluation of Antiphospholipid Syndrome (APS)
• Helps assess autoimmune clotting disorders
• Assists in investigating unexplained thrombosis
• Supports evaluation of recurrent pregnancy loss
• Complements other antiphospholipid antibody tests
• Requires only a peripheral blood sample

Why Doctors Recommend This Test

Doctors may recommend this test if a patient has:

• Recurrent blood clots
• Deep vein thrombosis (DVT)
• Pulmonary embolism
• Stroke at a young age
• Recurrent miscarriages
• Unexplained pregnancy complications
• Suspected Antiphospholipid Syndrome
• Systemic Lupus Erythematosus (SLE)
• Other autoimmune connective tissue disorders

Preparation Before Test

Sample Required

• Peripheral venous blood sample (Serum)

Preparation Guidelines

• No fasting is generally required.
• Continue medications unless advised otherwise by your physician.
• Inform your healthcare provider about anticoagulant therapy, autoimmune diseases, pregnancy history, or previous blood clotting events.
• Follow laboratory instructions before sample collection.

Reporting Time

Results are generally available within 3–7 working days, depending on laboratory methodology.

Who Should Take This Test?

This test is recommended for:

• Individuals with suspected Antiphospholipid Syndrome (APS)
• Patients with unexplained blood clots
• Women with recurrent miscarriages or pregnancy complications
• Patients with Systemic Lupus Erythematosus (SLE)
• Individuals with autoimmune diseases associated with thrombosis
• Patients referred by rheumatologists, hematologists, obstetricians, or physicians

Clinical Significance

A positive Beta 2 Glycoprotein 1 (β2GP1) IgA antibody result may indicate:

• Antiphospholipid Syndrome (APS)
• Autoimmune Thrombotic Disorder
• Increased Risk of Venous or Arterial Thrombosis
• Autoimmune Pregnancy Complications

Common clinical features associated with APS include:

• Deep vein thrombosis (DVT)
• Pulmonary embolism
• Stroke or transient ischemic attack (TIA)
• Recurrent miscarriages
• Stillbirth
• Pre-eclampsia
• Low platelet count (thrombocytopenia)
• Livedo reticularis (mottled skin appearance)

A positive Beta 2 Glycoprotein 1 IgA result should always be interpreted together with the patient's clinical history and other antiphospholipid antibody tests. Persistent positivity on repeat testing after at least 12 weeks, combined with compatible clinical findings, supports the diagnosis of Antiphospholipid Syndrome.